Weight-loss drugs are the health craze of 2023. According to the management of , America's largest retailer, drugs like Ozempic and Wegovy have begun impacting food sales.

Perhaps it shouldn't be surprising that shares of Novo Nordisk (NYSE: NVO), the pharmaceutical company behind Ozempic and Wegovy, have done well. The stock is up 36% since January and more than 70% over the past twelve months.

So, is it too late to enjoy this potentially monumental shift in the healthcare landscape? Or is Novo Nordisk's fortune a fad, like many previous health trends? Here's what you need to know.

Continue reading

Source Fool.com